Aptorum Group Limited (NASDAQ:APM) Sees Significant Drop in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the target of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 2,200 shares, a drop of 47.6% from the September 15th total of 4,200 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 15,400 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Aptorum Group

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. purchased a new stake in shares of Aptorum Group Limited (NASDAQ:APM) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned approximately 0.27% of Aptorum Group at the end of the most recent quarter. 3.80% of the stock is currently owned by institutional investors.

Aptorum Group Trading Down 2.6 %

Shares of NASDAQ:APM traded down $0.04 during trading hours on Friday, hitting $1.69. The company’s stock had a trading volume of 12,555 shares, compared to its average volume of 789,269. The firm’s fifty day moving average price is $2.58 and its 200 day moving average price is $4.34. Aptorum Group has a 52 week low of $1.35 and a 52 week high of $17.49.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.